MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

BioMarin Pharmaceutical Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

54.57 -0.26

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

53.99

Max

55.18

Pagrindiniai rodikliai

By Trading Economics

Pajamos

241M

426M

Pardavimai

80M

825M

P/E

Sektoriaus vid.

15.935

35.739

Pelnas, tenkantis vienai akcijai

1.44

Pelno marža

51.637

Darbuotojai

3,040

EBITDA

95M

319M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+77.7% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.2B

10B

Ankstesnė atidarymo kaina

54.83

Ankstesnė uždarymo kaina

54.57

Naujienos nuotaikos

By Acuity

20%

80%

42 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-07 16:58; UTC

Uždarbis

BMW Trims 2025 View, Citing Weaker Performance in China

2025-10-07 23:43; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025-10-07 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025-10-07 23:19; UTC

Rinkos pokalbiai

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025-10-07 22:40; UTC

Rinkos pokalbiai

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025-10-07 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 20:44; UTC

Karštos akcijos

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025-10-07 19:42; UTC

Rinkos pokalbiai

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025-10-07 19:23; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025-10-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025-10-07 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025-10-07 15:33; UTC

Rinkos pokalbiai

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025-10-07 15:25; UTC

Rinkos pokalbiai

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025-10-07 15:15; UTC

Rinkos pokalbiai

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025-10-07 15:04; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-10-07 15:04; UTC

Rinkos pokalbiai

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025-10-07 14:52; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

BioMarin Pharmaceutical Inc Prognozė

Kainos tikslas

By TipRanks

77.7% į viršų

12 mėnesių prognozė

Vidutinis 97.2 USD  77.7%

Aukščiausias 122 USD

Žemiausias 60 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioMarin Pharmaceutical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

22 ratings

18

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

59.405 / 62.19Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

42 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat